文献速递血栓与止血

阿伐曲泊帕治疗慢性免疫性血小板减少症的3期随机研究:一种新型血小板生成素受体激动剂

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.
PubMed 文献 · Br J Haematol · 2018-09-07

这项6个月、多中心、随机、双盲、平行组3期研究比较阿伐曲泊帕(20 mg/日)与安慰剂治疗成人慢性免疫性血小板减少症(血小板<30×10^9/L)。49例随机分组中,阿伐曲泊帕组(N=32)中位累积血小板应答周数为12.4周,优于安慰剂组(N=17)的0.0周(P<0.0001);第8天应答率65.63% vs 0.0%(P<0.0001)。

要点

  • 阿伐曲泊帕20 mg/日较安慰剂显著提高慢性ITP患者累积血小板应答周数。
  • 第8天血小板应答率阿伐曲泊帕组65.63%,安慰剂组0.0%(P<0.0001)。
  • 阿伐曲泊帕组合并ITP用药减少,常见不良事件为头痛和挫伤。

核心结论

  • 总体而言,阿伐曲泊帕耐受性良好且对慢性ITP治疗有效。

研究设计与样本

  • 6个月、多中心、随机、双盲、平行组3期研究,含开放标签延伸期,比较阿伐曲泊帕20 mg/日与安慰剂。
  • 纳入成人慢性免疫性血小板减少症且血小板计数<30×10^9/L者,共随机49例,阿伐曲泊帕组N=32,安慰剂组N=17。

主要发现

  • 中位累积血小板应答周数阿伐曲泊帕组12.4周 vs 安慰剂组0.0周(P<0.0001)。
  • 第8天血小板应答率阿伐曲泊帕组65.63% vs 安慰剂组0.0%(P<0.0001)。
  • 接受阿伐曲泊帕的患者合并ITP用药使用减少。
  • 安全性特征与2期研究一致,最常见不良事件为头痛和挫伤。

关键数值与推荐

  • 主要终点为无出血抢救治疗情况下血小板应答(血小板计数≥50×10^9/L)的累积周数。
  • 次要终点包括第8天血小板应答率和合并用药使用的减少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Avatrombopag, an oral thrombopoietin receptor agonist, was compared with placebo in a 6-month, multicentre, randomised, double-blind, parallel-group Phase 3 study, with an open-label extension phase, to assess the efficacy and safety of avatrombopag (20 mg/day) in adults with chronic immune thrombocytopenia (ITP) and a platelet count <30 × 109 /l (ClinicalTrials.gov identifier NCT01438840). The primary endpoint was the cumulative number of weeks of platelet response (platelet count ≥50 × 109 /l) without rescue therapy for bleeding; secondary endpoints included platelet response rate at day 8 and reductions in the use of concomitant medications. Amongst the 49 patients randomised, avatrombopag (N = 32) was superior to placebo (N = 17) in the median cumulative number of weeks of platelet response (12·4 vs. 0·0 weeks, respectively; P < 0·0001). At day 8, a greater platelet response rate was also observed for patients treated with avatrombopag compared with placebo (65·63% vs. 0·0%; P < 0·0001), and use of concomitant ITP medications was also reduced amongst patients receiving avatrombopag. The safety profile of avatrombopag was consistent with Phase 2 studies; the most common adverse events were headache and contusion. Overall, avatrombopag was well tolerated and efficacious for the treatment of chronic ITP.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018. PMID: 30191972. doi:10.1111/bjh.15573

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。